

Provided by:



## Rheumatology Case Management 2025-2026

**Rheumatology Case Management 2025-2026 - 11/18/2025**

**November 18, 2025**

**9:00 AM - 10:00 AM**

**Online/Rheumatology Conference Room 5 White**

### Target Audience

This program has been designed for ALLERGY AND IMMUNOLOGY, DERMATOLOGY, INTERNAL MEDICINE - Rheumatology, PEDIATRICS - Pediatric Rheumatology

### Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss diagnostic skills for rheumatologic diseases.
- 2 Describe common and uncommon manifestations of rheumatologic disease.
- 3 Discuss therapeutic advances and research for treatment of rheumatologic disease.

### Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Designation of Credit

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is for 1.00 contact hours.

**Pharmacists:** This activity is not approved for pharmacy contact hours

**PAs:** AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*<sup>™</sup> from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 credits for completing this activity.

### Acknowledgement of Commercial Support\*

None

For more information, please contact  
John Davis  
(215) 662-2792  
johdav@upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

| Name of individual    | Individual's role in activity   | Nature of Relationship(s) / Name of Ineligible Company(s)                                                                                                                                                                                                                                            |
|-----------------------|---------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Michael George, MD    | Other Planning Committee Member | Grant or research support-Glaxo Smith Kline Grant or research support-Janssen Pharmaceuticals (J&J) (Relationship has ended) Consulting Fee-Pfizer, Inc. (Relationship has ended) Grant or research support-CSL Behring (Relationship has ended) Grant or research support-Pfizer, Inc. - 06/29/2025 |
| Chadwick R Johr, MD   | Other Planning Committee Member | Paid consultant-Bristol-Myers Squibb Consulting Fee-Novartis / Amgen - 07/16/2025                                                                                                                                                                                                                    |
| Joshua F. Baker, MD   | Other Planning Committee Member | Consulting Fee-CorEvitas LLC Consulting Fee-Formation Bio (Relationship has ended) - 06/26/2025                                                                                                                                                                                                      |
| Sharon Kolasinski, MD | Other Planning Committee Member | Nothing to disclose - 06/27/2025                                                                                                                                                                                                                                                                     |
| Steffan Schulz, MD    | Other Planning Committee Member | Nothing to disclose - 07/17/2025                                                                                                                                                                                                                                                                     |
| Anupama Shahane, MD   | Course Director                 | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Astra Zeneca Pharmaceuticals (Relationship has ended) - 06/30/2025                                                                                                                                                        |
| Preethi Thomas, MD    | Other Planning Committee Member | Nothing to disclose - 06/27/2025                                                                                                                                                                                                                                                                     |
| Peter A Merkel, MD    | Other Planning Committee Member | Consulting Fee-AbbVie, Inc.  Grant or research support-AbbVie, Inc.  Consulting                                                                                                                                                                                                                      |

|                   |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                   |                                    | Fee-Astra Zeneca Pharmaceuticals  Consulting<br>Fee-Argenx  Grant or research support-Astra<br>Zeneca Pharmaceuticals  Consulting Fee-<br>Boehringer-Ingelheim  Grant or research<br>support-Boehringer-Ingelheim  Consulting<br>Fee-Bristol-Myers Squibb  Grant or research<br>support-Bristol-Myers Squibb  Consulting<br>Fee-Cabaletta (Relationship has<br>ended)  Consulting Fee-CSL Behring<br>(Relationship has ended)  Consulting Fee-<br>Dynacure (Relationship has<br>ended)  Consulting Fee-Genentech<br>(Relationship has ended)  Grant or research<br>support-Genentech (Relationship has<br>ended)  Grant or research support-Eicos<br>(Relationship has ended)  Grant or research<br>support-Electra (Relationship has<br>ended)  Consulting Fee-Sanofi Genzyme<br>(Relationship has ended)  Grant or research<br>support-Sanofi Genzyme (Relationship has<br>ended)  Consulting Fee-Immagene<br>(Relationship has ended)  Consulting Fee-<br>Interius  Consulting Fee-Janssen<br>Pharmaceuticals (J&J) (Relationship has<br>ended)  Consulting Fee-Kyverna  Stocks or<br>stock options, excluding diversified mutual<br>funds-Kyverna  Consulting Fee-Lifordi  Stocks<br>or stock options, excluding diversified mutual<br>funds of a publicly traded company-<br>Lifordi  Consulting Fee-Glaxo Smith<br>Kline  Grant or research support-Glaxo Smith<br>Kline  Consulting Fee-Inflarx GMBH<br>(Relationship has ended)  Grant or research<br>support-Inflarx GMBH (Relationship has<br>ended)  Consulting Fee-Magenta<br>(Relationship has ended)  Consulting Fee-<br>Novartis (Advanced Health Media)<br>(Relationship has ended)  Consulting Fee-<br>Neutrolis  Consulting Fee-NS<br>Pharma  Consulting Fee-Quell  Consulting<br>Fee-Takeda Pharmaceuticals  Grant or<br>research support-Takeda<br>Pharmaceuticals  Consulting Fee-Pfizer, Inc.<br>(Relationship has ended)  Consulting Fee-<br>Q32  Consulting Fee-Regeneron<br>Pharmaceuticals, Inc. (Relationship has<br>ended)  Consulting Fee-Sparrow  Consulting<br>Fee-Argenx (Relationship has<br>ended)  Consulting Fee-Visterra  Consulting<br>Fee-Kinevant  Consulting Fee-<br>Sparrow  Consulting Fee-iCell  Royalties or<br>Patent Beneficiary-UpToDate - 06/27/2025 |
| Rennie Rhee, MD   | Other Planning Committee<br>Member | Consulting Fee-Novartis (Advanced Health<br>Media) - 06/27/2025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Nora Sandorfi, MD | Other Planning Committee           | Consulting Fee-Janssen Pharmaceuticals                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

|                         |                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------|---------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                         | Member                          | (J&J)   Paid consultant-BMS   Membership on Advisory Committees or Review Panels, Board Membership, etc.- Immunovant   Advisor-Novartis / Amgen - 06/29/2025                                                                                                                                                                                                                                                                                                                                                                                      |
| Carla Scanzello, MD     | Other Planning Committee Member | Nothing to disclose - 06/09/2025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Ethan Craig, MD, MHS    | Other Planning Committee Member | Employment-Penn Specialty Pharmacy   Advisor-Penn Home Infusion   Honoraria-Lilly (Relationship has ended)   Consulting Fee-Calico (Relationship has ended)   Consulting Fee-Janssen Pharmaceuticals (J&J) (Relationship has ended) - 06/11/2025                                                                                                                                                                                                                                                                                                  |
| Alexis Ogdie, MD, MSPH  | Other Planning Committee Member | Consulting Fee-Pfizer, Inc.   Grant or research support-Janssen Pharmaceuticals (J&J)   Consulting Fee-CorEvitas   Grant or research support-AbbVie, Inc.   Grant or research support-Novartis / Amgen   Grant or research support-Pfizer, Inc.   Consulting Fee-Janssen Pharmaceuticals (J&J)   Consulting Fee-Glaxo Smith Kline   Consulting Fee-UCB   Consulting Fee-Bristol-Myers Squibb   Consulting Fee-Novartis / Amgen   Consulting Fee-AbbVie, Inc.   Consulting Fee-Takeda Pharmaceuticals   Ownership-Research Pathfinder - 07/15/2025 |
| Naomi Amudala, CRNP RN  | Nurse Planner                   | Speakers Bureau-Amgen   Paid consultant-Johnson & Johnson - 04/28/2025                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Shubhasree Banerjee, MD | Co-Director                     | Nothing to disclose - 06/27/2025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Chris T Derk, MD        | Other Planning Committee Member | Nothing to disclose - 06/27/2025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Jonathan Dunham, MD     | Other Planning Committee Member | Nothing to disclose - 06/27/2025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Rachel Dayno, MD        | Other Planning Committee Member | Nothing to disclose - 06/30/2025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Kimberly DeQuattro, MD  | Other Planning Committee Member | Nothing to disclose - 12/02/2024                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Ian Cooley, MD          | Other Planning Committee Member | Nothing to disclose - 06/27/2025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Meghan J Anderson, DO   | Other Planning Committee Member | Nothing to disclose - 06/27/2025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Rachel Galvao, MD       | Faculty                         | Nothing to disclose - 07/11/2025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected